Kiniksa Pharmaceuticals International, plc

For the period ended Dec 31, 2025. Filed Feb 24, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 24, 2026

KNSA$98.76+5.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands, except share and per share amounts)


· · December 31, · · December 31,
· · 2025 · · 2024
Assets · · · ·
Current assets: · · · ·
Cash and cash equivalents	$165,596	$183,581
Short-term investments	248,478	60,046
Accounts receivable, net	15,594	41,724
Inventory	54,895	26,364
Prepaid expenses and other current assets	42,614	20,084
Total current assets	527,177	331,799
Property and equipment, net	1,943	662
Operating lease right-of-use assets	9,807	10,376
Other long-term assets	11,307	10,315
Intangible asset, net	15,250	16,250
Deferred tax assets	198,149	211,151
Total assets	$763,633	$580,553

Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable	$2,028	$2,039
Accrued collaboration expenses	70,015	48,157
Accrued expenses	42,020	32,355
Operating lease liabilities	2,987	1,993
Other current liabilities	22,134	16,077
Total current liabilities	139,184	100,621
Non-current liabilities:
Non-current deferred revenue	31,811	31,811
Non-current operating lease liabilities	6,510	7,862
Other long-term liabilities	18,522	1,823
Total liabilities	196,027	142,117
Commitments and contingencies (Note 16)
Shareholders’ equity:
Class A ordinary shares, par value of $0.000273235 per share; 45,659,424 shares and 41,881,319 shares issued and outstanding as of December 31, 2025 and 2024, respectively	12	11
Class B ordinary shares, par value of $0.000273235 per share; 1,795,158 shares issued and outstanding as of December 31, 2025 and 2024	1	1
Class A1 ordinary shares, $0.000273235 par value; 12,781,964 shares issued and outstanding as of December 31, 2025 and 2024	4	4
Class B1 ordinary shares, $0.000273235 par value; 16,057,618 shares issued and outstanding as of December 31, 2025 and 2024	4	4
Additional paid-in capital	1,029,748	959,722
Accumulated other comprehensive loss	(25)	(163)
Accumulated deficit	(462,138)	(521,143)
Total shareholders’ equity	567,606	438,436
Total liabilities and shareholders’ equity	$763,633	$580,553

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.